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Differences in NT-proBNP Response and
Prognosis in Men and Women With Heart
Failure With Reduced Ejection Fraction
Melissa A. Daubert , MD; Eric Yow, MS; Huiman X. Barnhart, PhD; Ileana L. Piña , MD, MPH; Tariq Ahmad, MD;
Eric Leifer, PhD; Lawton Cooper , MD, MPH; Patrice Desvigne-Nickens , MD; Mona Fiuzat, PharmD;
Kirkwood Adams, MD; Justin Ezekowitz , MBBCh, MSc; David J. Whellan, MD, MHS; James L. Januzzi , MD;
Christopher M. O’Connor, MD; G. Michael Felker , MD, MHS
BACKGROUND: NT-proBNP (N-terminal pro-B-type natriuretic peptide) is a prognostic biomarker in heart failure (HF) with reduced ejection fraction. However, it is unclear whether there is a sex difference in NT-proBNP response and whether the
therapeutic goal of NT-proBNP ≤1000 pg/mL has equivalent prognostic value in men and women with HF with reduced ejection fraction.
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METHODS AND RESULTS: In a secondary analysis of the GUIDE-IT (Guiding Evidence Based Therapy Using Biomarker Intensified
Treatment) trial we analyzed trends in NT-proBNP and goal attainment by sex. Differences in clinical characteristics, HF treatment, and time to all-cause death or HF hospitalization were compared. Landmark analysis at 3 months determined the prognostic value of early NT-proBNP goal achievement in men and women. Of the 286 (32%) women and 608 (68%) men in the
GUIDE-IT trial, women were more likely to have a nonischemic cause and shorter duration of HF. Guideline-directed medical
therapy was less intense over time in women. The absolute NT-proBNP values were consistently lower in women; however,
the change in NT-proBNP and clinical outcomes were similar. After adjustment, women achieving the NT-proBNP goal had an
82% reduction in death or HF hospitalization compared with a 59% reduction in men.
CONCLUSIONS: Men and women with HF with reduced ejection fraction had a similar NT-proBNP response despite less intensive HF treatment among women. However, compared with men, the early NT-proBNP goal of ≤1000 pg/mL had greater
prognostic value in women. Future efforts should be aimed at intensifying guideline-directed medical therapy in women, which
may result in greater NT-proBNP reductions and improved outcomes in women with HF with reduced ejection fraction.
REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01685840.
Key Words: N-terminal pro-B-type natriuretic peptide ■ heart failure ■ women

T

he prevalence of heart failure (HF) with reduced
ejection fraction (HFrEF) increases with age for
both men and women; however, there are intriguing sex-
specific differences in predisposing factors,
medical treatment, health-related quality of life (QoL),
and clinical outcomes.1–3 Women with HFrEF are frequently older and are more likely than men to have a
nonischemic HF cause.3–9 Women experience more

severe symptoms and have a worse QoL for a similar
burden of HF.3,10 Guideline-directed medical therapy
(GDMT) is often underutilized in women, and women
are less likely to be referred for cardiac rehabilitation
and cardiac resynchronization therapy, despite the
greater mortality benefits of these interventions in
women compared with men.1–3,5,11,12 Finally, there are
conflicting data regarding clinical outcomes in women
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CLINICAL PERSPECTIVE
What Is New?

• In a population with advanced heart failure with
reduced ejection fraction, women were treated
less intensely with guideline-
directed medical
therapy than men.
• Absolute NT-proBNP (N-terminal pro-B-type
natriuretic peptide) values were consistently
lower in women, yet the adjusted change in NT-
proBNP, NT-
proBNP early goal achievement,
and clinical outcomes were similar between
men and women with heart failure with reduced
ejection fraction.

What Are the Clinical Implications?

• Among men and women achieving the NT-
proBNP goal of ≤1000 pg/mL at 3 months,
there was a lower rate of death and heart failure
hospitalization in women than in men, suggesting that women with heart failure with reduced
ejection fraction may derive greater benefit from
early NT-proBNP reductions.

in HFrEF. Previous studies have evaluated baseline
NT-proBNP concentrations and the association with
clinical outcomes in men and women.15–17 However,
to date, no study has serially evaluated NT-proBNP
and assessed the sex-specific NT-proBNP response
and clinical outcomes in men and women with HFrEF.
Furthermore, the therapeutic target of reducing NT-
proBNP to <1000 pg/mL has been uniformly applied
to both sexes; however, it is unclear whether this NT-
proBNP goal has equivalent prognostic value in both
men and women.
The GUIDE-
IT (Guiding Evidence Based Therapy
Using Biomarker Intensified Treatment) trial was a large,
randomized clinical trial that evaluated the impact of
biomarker-guided care at 45 sites in the United States
and Canada by comparing NT-proBNP–guided management with usual care in the HFrEF population.18 In
this secondary analysis of the GUIDE-IT trial, we studied the longitudinal trends in NT-proBNP among men
and women with HFrEF in order to increase the understanding of sex-specific differences in HFrEF and identify opportunities to optimize treatment and improve
clinical outcomes.

METHODS
Nonstandard Abbreviations and Acronyms
Downloaded from http://ahajournals.org by on June 13, 2021

CHAMP-HF
GDMT
GUIDE-IT

HFrEF
KCCQ
KorHF
NT-proBNP
QoL

Change the Management of
Patients With Heart Failure
guideline-directed medical therapy
Guiding Evidence Based Therapy
Using Biomarker Intensified
Treatment
heart failure with reduced
ejection fraction
Kansas City Cardiomyopathy
Questionnaire
Korean Heart Failure Registry
N-terminal pro-B-type natriuretic
peptide
quality of life

with HFrEF. Some studies indicate higher rates of death
and HF hospitalization, while others have found that
women with HFrEF have fewer HF hospitalizations and
lower mortality compared with men with HFrEF.3,4,13,14
Further evaluation of the biological mechanisms underlying these sex differences is needed to optimize
the care of women with HFrEF.
Insight into the pathophysiologic underpinnings of
sex-specific differences may be gained through observation of the longitudinal response in NT-proBNP
(N-terminal pro-B-type natriuretic peptide), one of the
more powerful diagnostic and prognostic biomarkers

Data Availability
Qualified researchers trained in human subject confidentiality protocols may request access to the data
that support the findings of this study by contacting the National Heart, Lung, and Blood Institute
Biological Specimen and Data Repository Information
Coordination Center.

Study Design and Population
The study design and outcomes for the GUIDE-IT
trial have been previously published.18,19 Briefly, between January 16, 2013, and September 20, 2016,
stable patients with HFrEF (ejection fraction ≤40%)
were enrolled and randomized to a strategy of usual
care with NT-proBNP guidance or usual clinically directed care. Patients in the biomarker-guided arm
were treated with usual care plus serial NT-proBNP
measurements with a goal to decrease NT-proBNP
concentration <1000 pg/mL, whereas those in the
usual care arm received standard clinically guided
care. Patients were to be followed for a minimum
of 12 months and a maximum of 24 months. The
GUIDE-IT trial was designed to include 1100 patients
but was stopped by the data safety monitoring board
for futility after 894 patients (81% of planned) were
enrolled.18 No difference in achieved NT-
proBNP
concentrations or clinical outcomes was found between the study arms and the medical management
of both study groups was comparable. The study
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was funded by the National Heart, Lung, and Blood
Institute and approved by the institutional review
board at each study site. All patients provided written informed consent to participate.
In both study arms, NT-
proBNP levels were
collected at baseline and every 3 months through
12 months and analyzed at a central core laboratory.
Patients and providers were blinded to core laboratory NT-proBNP results. In the biomarker-guided
arm, NT-
proBNP levels were also ascertained at
local laboratories for use by treating providers.
The study protocol specified clinical interventions
to be considered to achieve the NT-proBNP goal
of <1000 pg/mL, but specific management decisions were at the discretion of the treating physician. Patients randomized to the usual care group
received treatment based on clinical practice guidelines. Sites were asked not to perform open-label
assessment of natriuretic peptides in the usual care
group. Provider reasons for not titrating HF medications were collected at study visits.
All patients with an NT-proBNP measurement at
baseline were included in this analysis cohort. Clinical
characteristics, serial NT-
proBNP concentrations,
GDMT, and clinical outcomes through 24 months
were evaluated according to sex. The GDMT score,
as reported by Januzzi et al,20 was used to assess
sex differences in treatment with HF therapies associated with mortality reduction in HFrEF. The primary
clinical outcome was time to a composite of all-cause
death or HF hospitalization. Secondary outcomes
were time to all-cause death, time to HF hospitalization, time to cardiovascular hospitalization, and
time to a composite of cardiovascular death or HF
hospitalization. All adverse events were adjudicated
by a clinical end point committee using prespecified
criteria. Health-related QoL was measured using the
Kansas City Cardiomyopathy Questionnaire (KCCQ),
which is scored 0 to 100, with lower scores indicating
a poorer health status.

Statistical Analysis
Descriptive data are presented as frequencies and
percentages for categorical variables and mean±SD
or median with 25th and 75th interquartile range
(IQR) for continuous variables. For continuous variables, differences were assessed using Wilcoxon
rank sum test, and for categorical variables, differences were assessed using chi-square test. In the
case of low cell counts, the treatment group differences were tested using Fisher exact method. For
count data, such as medication adjustments and
visit frequency, Poisson regression with offset of
follow-up time was used to assess differences. Sex
differences in NT-proBNP concentrations were adjusted for age, race, body mass index (BMI), chronic

Sex Differences in NT-proBNP in HFrEF

kidney disease, diabetes mellitus, and ischemic cardiomyopathy.21 For time-to-event analyses, with time
starting at randomization, unadjusted event rates
were estimated using Kaplan-M eier curves and 95%
CIs; group differences were tested using log-rank
test. Cox proportional hazards regression models
were used to examine the associations between sex
and outcomes while adjusting for covariates that
were statistically significant in the univariate model
or clinically relevant. The covariates included were
age, race, BMI, hypertension, diabetes mellitus,
smoking, chronic kidney disease, peripheral artery
disease, atrial fibrillation, coronary artery disease,
ischemic cardiomyopathy, myocardial infarction,
New York Heart Association class III/IV, ejection
fraction, duration of HF, log of baseline NT-proBNP,
biomarker-guided arm, and QoL by KCCQ score.
To minimize bias attributable to missing variables,
multiple imputation using the fully conditional specification method was implemented for the modeling.
Landmark time-to-event analyses at 3 months were
performed on patients alive at that time. Cox regression analysis was performed and included the same
covariates as above, as well as median visit count
until the landmark, median dose adjustment until the
landmark, GDMT score at the landmark, log of 3-
month NT-proBNP, and NT-proBNP ≤1000 pg/mL at
the landmark. To assess whether there was a differential benefit for women and men who achieved
the NT-proBNP goal at 3 months, we assessed the
interaction of sex and NT-proBNP goal achievement
at the landmark in the Cox regression analysis. An
exploratory analysis of adjusted data used a grid
search to find the 3-month NT-proBNP concentration in men and women at which there was a shift in
linear association with the time-to-event outcome of
death or HF hospitalization.22 A 2-piece cubic spline
model with transformation was used to demonstrate
the optimal 3-month NT-proBNP cut point, defined
as the NT-proBNP concentration below which there
was a significant decrease in the adjusted hazard for
death or HF hospitalization. The threshold for statistical significance was 2-sided with a type I error rate
of 0.05. The assumption of proportional hazards for
sex was assessed using supremum test and found
to be nonsignificant in the Cox regression models.
Analyses were performed using SAS version 9.4
(SAS Institute Inc.).

RESULTS
There were 286 (32%) women and 608 (68%) men in
the GUIDE-IT trial (Figure 1). The baseline characteristics
of men and women are shown in Table 1. Women had
greater racial diversity, a higher BMI, and fewer coronary
artery disease risk factors compared with men. Women
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Table 1. Baseline Clinical Characteristics in Men and
Women in GUIDE-IT

GUIDE-IT
Trial
(n=894)

Men

Women

(n=608)

(n=286)

Men with
3-month NT-proBNP

Women with
3-month NT-proBNP

(n=480)

(n=217)

Figure 1. CONSORT diagram.
Study flow diagram of secondary analysis population and
subgroup. GUIDE-IT indicates Guiding Evidence Based Therapy
Using Biomarker Intensified Treatment; and NT-
proBNP, N-
terminal pro-B-t ype natriuretic peptide.
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were more likely to have a nonischemic HF cause, a
shorter duration of HF, and a higher ejection fraction at
baseline, but, compared with men, women had a lower
QoL score. There was no difference in biomarker-guided
therapy allocation according to sex. Pharmacologic
treatment by medication class was similar between men
and women at baseline (Table 2). A relatively low percentage of either sex were at ≥100% of the target dose
for β-blockers and angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs)
at baseline. However, the GDMT score was significantly
lower in women at baseline, 3 months, and 12 months.
At 1 year, a significantly greater percentage of men than
women were titrated up to ≥100% of target doses of β-
blockers and a similar trend was seen for ACEIs or ARBs
(Figure 2). Women had significantly fewer dose adjustments than men: 4.0 (IQR, 2.0–7.0) versus 5.0 (IQR, 2.0–
8.0) (P<0.001). Reasons for not titrating dose are listed in
Figure 3 and differed between men and women. Women
also had significantly fewer clinical visits compared with
men: 9.3±5.0 versus 10.0±5.8, respectively (P=0.002).
The absolute NT-proBNP values were consistently
lower in women; however, the trend in NT-
proBNP
among men and women with HFrEF was similar
over time (Figure 4). Univariate analysis of the sex-
specific NT-
proBNP response revealed that women
had a significantly lower NT-
proBNP concentration
by 3 months, but after adjusting for age, race, BMI,
chronic kidney disease, diabetes mellitus, and

Women (n=286)

Men (n=608)

P Value

Age, y

60.6±15.0

61.9±13.3

0.36

Race (Black)

127 (44.4)

197 (32.4)

<0.001

BMI, kg/m2

31.8±9.6

29.5±7.2

0.001

Hypertension

210 (73.4)

496 (81.6)

0.008

Hyperlipidemia

157 (54.9)

367 (60.4)

0.15

Diabetes mellitus

142 (49.7)

268 (44.1)

0.13

Smoking

80 (28.0)

224 (36.8)

0.01

Atrial fibrillation

99 (34.6)

259 (42.6)

0.03

Chronic kidney
disease

87 (32.4)

243 (40.0)

0.007

Peripheral artery
disease

17 (5.9)

77 (12.7)

0.002

Coronary artery
disease

102 (35.7)

308 (50.7)

<0.001

Myocardial
infarction

54 (18.9)

197 (32.4)

<0.001

Ischemic
cardiomyopathy

111 (38.8)

336 (55.3)

<0.001

HF duration*, mo

8 (1.0–48.0)

20 (1.0–72.0)

0.003

NYHA class III/IV

127 (44.4)

248 (40.8)

0.34

Ejection fraction,
%

25.1±8.2

23.9±8.3

0.03

QoL score by
KCCQ

53.1±21.4

59.6±22.0

<0.001

Biomarker-guided
therapy

139 (48.6)

307 (50.5)

0.62

Values are mean±SD or number (percentage) unless otherwise noted.
BMI indicates body mass index; GUIDE-IT, Guiding Evidence Based Therapy
Using Biomarker Intensified Treatment; HF, heart failure; KCCQ, Kansas City
Cardiomyopathy Questionnaire; NYHA, New York Heart Association; and
QoL, quality of life.
*Median (interquartile range).

ischemic cardiomyopathy, there were no significant
sex differences in NT-proBNP response (Table 3). The
median follow-up for clinical events was 14.7 months
(IQR, 6.6–23.5 months) with a similar duration in men
and women (14.7 months [IQR, 6.7–23.7 months] and
14.9 months [IQR, 6.2–
22.6 months], respectively).
There was no difference between men and women
for the primary outcome of all-
cause death or HF
hospitalization (Figure 5). Unadjusted analysis of
secondary outcomes demonstrated significantly fewer
deaths among women at 12 months; however, this
did not remain statistically significant after adjustment
(Table 4).
To further explore the impact of early NT-proBNP
goal achievement on outcomes among men and
women, a 3-month landmark analysis was performed
and included the 697 (77.9%) patients who were alive
and had a 3-
month NT-
proBNP concentration. The
analysis excluded 197 patients, of whom 49 had died,
53 had <3 months of follow-up, and 95 were missing
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Table 2. Pharmacologic Treatment in Men and Women in
the GUIDE-IT Trial
Women (n=286)

Men (n=608)

P Value

Medications at baseline (% of patients)
ACEI or ARB

78.1

80.1

0.53

β-blocker

95.4

94.7

0.74

Mineralocorticoid
receptor antagonist

48.4

50.5

0.57

6 (4–8)

7 (4–9)

<0.001

GDMT score*

Percentage at ≥100% of target dose at baseline
ACEI or ARB
β-Blocker
Mineralocorticoid
receptor antagonist

15.0

20.3

0.11

7.5

6.4

0.55

79.3

69.5

0.04

Medications at 3 mo (% of patients)
ACEI or ARB

79.5

77.1

0.51

β-Blocker

94.9

95.3

0.85

Mineralocorticoid
receptor antagonist

55.8

58.7

0.47

7 (5–10)

8 (5.75–10)

0.017

GDMT score*

Percentage at ≥100% of target dose at 3 mo
ACEI or ARB

21.5

26.3

0.25

β-Blocker

6.8

9.2

0.31

Mineralocorticoid
receptor antagonist

80.3

75.6

0.32

Medications at 1 y (% of patients)

Downloaded from http://ahajournals.org by on June 13, 2021

ACEI or ARB

73.8

78.1

0.31

β-Blocker

93.1

93.9

0.70

Mineralocorticoid
receptor antagonist

52.5

55.0

0.63

7 (4.5–10)

8 (6–11)

0.009

GDMT score*

Percentage at ≥100% of target dose at 1 y
ACEI or ARB

22.

31.8

0.08

β-Blocker

6.2

16.3

0.003

Mineralocorticoid
receptor antagonist

79.8

73.4

0.29

ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin
II receptor blocker; GDMT, guideline directed medical therapy; and GUIDE-IT,
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment.
*Median (interquartile range).

the 3-
month NT-
proBNP measurement. Differences
in clinical characteristics between men and women
in this subgroup were similar to that of the whole cohort (Table S1). In the 3-month landmark analysis of
the primary outcome of death or HF hospitalization,
there was no difference between men and women for
the primary outcome after adjustment (hazard ratio
[HR], 1.11; 95% CI, 0.82–1.51 [P=0.48]). However, longer HF duration increased the hazard for death or HF
hospitalization (HR, 1.22; 95% CI, 1.12–1.34 [P<0.001]),
while achieving the NT-proBNP goal of ≤1000 pg/mL
at 3 months decreased the hazard (HR, 0.41; 95% CI,
0.25–0.68 [P<0.001]).

Evaluation of sex differences in NT-proBNP goal
achievement at 3 months revealed that women were
more likely to achieve the early goal, but this did not
remain statistically significant after adjustment for
clinical characteristics and HF treatment (odds ratio
[OR], 0.50; 95% CI, 0.08–3.03 [P=0.45]). However,
among women achieving the NT-proBNP ≤1000 pg/
mL at 3 months, there was an 82% reduction in death
or HF hospitalization (HR, 0.18; 95% CI, 0.07–0.45
[P<0.001]). In comparison, men achieving the early
NT-proBNP goal had a 59% reduction in the primary
outcome (HR, 0.41; 95% CI, 0.25–0.68 [P<0.001])
(Figure 6). Exploration of the interaction between sex
and achieved 3-month NT-proBNP goal on clinical
outcomes suggested a trend that women benefitted
more than men from early NT-proBNP goal achievement (interaction P=0.11).
Additionally, the 3-month NT-proBNP concentration below which women had a significant reduction
in the adjusted hazard for the primary outcome was
substantially lower than the NT-proBNP threshold in
men (Figure S1). After adjustment, an NT-
proBNP
threshold of ≤5410 pg/mL at 3 months was associated with a significantly lower rate of death or
HF hospitalization in men, whereas an NT-proBNP
threshold of ≤1260 pg/mL at 3 months was predictive of lower mortality or HF hospitalization in women.
Furthermore, the magnitude of benefit of lowering NT-
proBNP was greater for women. For every 100-pg/
mL reduction in NT-proBNP below the sex-specific
threshold, women had a 21% lower rate of death
or HF hospitalization (HR, 0.79; 95% CI, 0.68–0.91
[P=0.001]), whereas men only had a 4% reduction in
the primary outcome (HR, 0.96; 95% CI, 0.95–0.98
[P<0.001]).

DISCUSSION
This secondary analysis of the GUIDE-IT trial revealed
important insights about sex-specific management and
the longitudinal NT-proBNP response among men and
women with HFrEF. Compared with men, women had
fewer clinical risk factors and received less intensive
GDMT, especially by 12 months. Exploratory analysis
suggested that when the difference in clinical risk and
intensity of HF treatment between men and women is
adjusted for, early NT-proBNP goal achievement may
benefit women more than men. Furthermore, incremental reductions in NT-proBNP below sex-specific
thresholds have greater prognostic significance in
women than men.
Similar to prior studies, women with HFrEF in the
GUIDE-IT trial were more racially diverse, had higher
BMIs and fewer coronary artery disease risk factors,
and were more likely to have a nonischemic cause of
HF.3–5,7,9 Baseline KCCQ scores were significantly lower
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Figure 2. Sex differences in target dosing of guideline-directed medical therapy (GDMT) at 1 year.
Pie charts indicating the proportion of men and women achieving target doses of β-blocker therapy (top row) and angiotensin-
converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) therapy (bottom row) at 1 year. Men were significantly more
likely to be at or above target doses than women. *P=0.003; †P=0.08. NT-proBNP indicates N-terminal pro-B-t ype natriuretic peptide.

among women than men, despite having a shorter duration of HF and a higher mean ejection fraction. This
sex disparity in KCCQ scores has also been observed
in other HFrEF studies and warrants further investigation as to why HF imparts a lower QoL among women
than men.3,10 A greater understanding of psychosocial
factors and the influence of comorbid conditions, such
as anxiety and depression, that may be contributing
to these sex differences could allow for more targeted
therapeutic strategies.
Earlier HFrEF studies have reported pharmacologic undertreatment of women at baseline; however,

more contemporary studies demonstrate this treatment differential is narrowing.3–5,9,15 Yet even in these
more recent studies, treatment was largely defined
as the percent utilization in each class of GDMT. In
contrast, the GUIDE-IT trial uniquely captured pharmacologic treatment over time with granular detail
about the percentage of patients at or above target
doses of GDMT and reasons for not titrating dose
during clinical visits.23 In this sex-stratified treatment
analysis, a similar proportion of men and women
were taking guideline-recommended medications for
HF at baseline; however, women were at significantly
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Figure 3. Reasons for not titrating medications by sex.
Bar graph indicating the reasons for not titrating medication dose in men and women. NT-proBNP indicates N-terminal pro-B-type
natriuretic peptide.
Downloaded from http://ahajournals.org by on June 13, 2021

lower GDMT intensity at baseline and throughout the
course of the study, indicating a lower dose application
of HF therapies known to have a mortality benefit. At
1 year, men were significantly more likely to be at or
above the target dose for β-blockers compared with
women, and a similar trend was noted for ACEIs or
ARBs. These results are consistent with findings from
the CHAMP-HF (Change the Management of Patients
With Heart Failure) registry, which found that female
sex was associated with lower utilization of β-blockers
and ACEIs or ARBs.24 This undertreatment of women
has important implications for clinical outcomes and is
also significant for the potential impact on NT-proBNP.
Januzzi et al20 demonstrated that escalating the dose
of β-blocker therapy has the greatest influence on lowering NT-proBNP concentrations (OR, 1.38; 95% CI,
1.10–1.72 [P=0.005]) followed by ACEI therapy (OR,
1.11; 95% CI, 1.01–1.21 [P=0.03]). Had women been
treated as intensely as men over time with GDMT,
women may have achieved even lower concentrations
of NT-proBNP. Efforts should be made to increase the
intensity of GDMT in order to optimize HF treatment
and improve clinical outcomes in women with HFrEF.
The lower achievement of target dose and undertreatment among women is at least partly explained
by the fewer dose titrations in women compared with
men. Provider reasoning for not titrating dose differed

between men and women with men more often being
"at the maximum tolerated dose," while women were
not titrated because they were "below NT-
proBNP
goal" or because of the provider’s "clinical decision."
Lack of titrating as a result of achieving the NT-proBNP
goal may disadvantage women more than men. In the
landmark analysis, women only began to have a significant reduction in adverse outcomes once NT-proBNP
concentrations were <1260 pg/mL at 3 months.
Therefore, women in whom GDMT was not intensified
were denied the benefit that further biomarker reduction could have potentially conferred. Lack of dose
titration because of the provider’s discretion may reflect that women with HFrEF are perceived differently
than men with HFrEF and such sex bias can influence
clinical HF management.25–27 Greater understanding
of these perceived differences is needed to overcome
the obstacles that may hinder the intensifying GDMT
in women.
This is the first study, to our knowledge, to longitudinally evaluate the sex-
specific NT-
proBNP
response to HF treatment and assess the association with clinical outcomes in men and women with
HFrEF. Furthermore, existing data are conflicting as
to whether NT-proBNP has the same prognostic significance in men and women with HFrEF.15,16 In the
study by Franke and colleagues,15 NT-proBNP was
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Male
Female
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286

480
217

392
182

331
144

308
140

230
107
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151
68

131
57
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Figure 4. Change in NT-proBNP (N-terminal pro-B -type natriuretic peptide) in men and women with heart failure with
reduced ejection fraction.
The trend in NT-proBNP was similar between men and women. Dots are median NT-proBNP (pg/mL); whiskers are interquartile range.

found to be equally predictive of mortality in men and
women. In contrast, an analysis of KorHF (Korean
Heart Failure Registry) found that NT-proBNP had
greater predictive value for death and HF readmission in men than women.16

In GUIDE-IT, women had lower absolute NT-proBNP
concentrations; however, the difference NT-proBNP
goal achievement and absolute NT-proBNP reduction
was not significantly different after adjustment for factors known to influence NT-proBNP levels.21 This could

Table 3. NT-proBNP Response According to Sex
Women (n=286)

Men (n=608)

Unadjusted P Value

Adjusted P Value*

NT-proBNP (pg/mL) at baseline

2349 (1382 to 4946)

NT-proBNP (pg/mL) at 3 mo

1587 (623 to 3343)

2803 (1521 to 5573)

0.10

0.56

2086 (883 to 4250)

0.01

NT-proBNP <1000 at 3 mo

0.61

79 (36.4)

135 (28.1)

0.03

0.46

NT-proBNP Δ from baseline to 3 mo

−401 (−1416 to 281)

−543 (−1709 to 280)

0.69

0.91

NT-proBNP (pg/mL) at 6 mo

1351 (446 to 3510)

1685 (748 to 4093)

0.09

0.99

NT-proBNP <1000 at 6 mo

77 (42.3)

129 (32.9)

0.03

0.17

−554 (−1650 to 517)

−644 (−1861 to 358)

0.51

0.77

NT-proBNP (pg/mL) at 9 mo

1116 (361 to 2909)

1549 (600 to 3205)

0.07

0.67

NT-proBNP <1000 at 9 mo

61 (42.4)

105 (31.7)

0.03

0.09

NT-proBNP Δ from baseline to 9 mo

−574 (−2005 to 73)

−814 (−2244 to 151)

0.38

0.87

NT-proBNP (pg/mL) at 12 mo

1201 (387 to 2679)

1404 (529 to 3263)

0.15

0.15

NT-proBNP <1000 at 12 mo

65 (46.4)

126 (40.9)

0.30

0.63

−661 (−2003 to 214)

−829 (−2256 to 127)

0.63

0.98

NT-proBNP Δ from baseline to 6 mo

NT-proBNP Δ from baseline to 12 mo

Values are median (interquartile range) or number (% of evaluable patients). Δ indicates change; and NT-proBNP, N-terminal pro-B-t ype natriuretic peptide.
*Adjusted for age, race, body mass index, chronic kidney disease, diabetes mellitus, and ischemic cardiomyopathy.
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Figure 5. Clinical outcomes in men and women with heart failure (HF) with reduced ejection fraction.
The Kaplan-Meier curves for the primary outcome of death or HF hospitalization (upper left) and secondary outcomes of death
(upper right); HF hospitalization (lower left) and cardiovascular hospitalization (lower right). Clinical outcomes were similar in
men and women.

explain the similar clinical outcomes between men
and women. Greater reductions in NT-proBNP have
been associated with improved clinical outcomes.28
Table 4.

It is possible that if women had received GDMT of
equivalent intensity through 12 months, they may have
had a greater absolute reduction in NT-proBNP and

Clinical Outcomes in Men and Women With HFrEF Through 24 Months
Women* (n=286)

Men* (n=608)

Unadjusted HR
(95% CI)

P Value

Adjusted HR†
(95% CI)

P Value

85 (34.6)

198 (36.5)

0.94 (0.73 to 1.21)

0.64

0.91 (0.69 to 1.20)

0.49

12 mo
Composite: death or HF
hospitalization
Death

21 (8.9)

74 (14.4)

0.61 (0.37 to 0.99)

0.04

0.72 (0.43 to 1.21)

0.22

HF hospitalization

78 (32.0)

164 (31.0)

1.04 (0.80 to 1.36)

0.77

1.02 (0.76 to 1.37)

0.91

Cardiovascular hospitalization

134 (54.4)

309 (56.8)

0.91 (0.74 to 1.11)

0.36

0.87 (0.70 to 1.08)

0.20

Composite: cardiovascular
death or HF hospitalization

84 (34.3)

190 (35.1)

0.97 (0.75 to 1.25)

0.81

0.92 (0.69 to 1.21)

0.55

101 (35.3)

243 (40.0)

0.93 (0.74 to 1.17)

0.54

0.96 (0.75 to 1.24)

0.77

Death

38 (21.3)

105 (24.3)

0.78 (0.54 to 1.13)

0.19

0.91 (0.61 to 1.37)

0.66

HF hospitalization

89 (40.3)

199 (43.1)

1.0 (0.78 to 1.28)

0.98

1.03 (0.78 to 1.35)

0.86

Cardiovascular hospitalization

145 (62.5)

351 (70.1)

0.87 (0.72 to 1.06)

0.16

0.86 (0.70 to 1.07)

0.17

Composite: cardiovascular
death or HF hospitalization

98 (44.0)

230 (47.7)

0.95 (0.75 to 1.20)

0.68

0.96 (0.74 to 1.24)

0.75

24 mo
Composite: death or HF
hospitalization

HF indicates heart failure; HFrEF, heart failure with reserved ejection fraction; and HR, hazard ratio.
*Event rates are expressed as number (percentage).
†
Adjusted for baseline clinical characteristics.
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Figure 6. Clinical outcomes in men and women by early NT-proBNP (N-terminal pro-B -type natriuretic peptide) goal
achievement.
Clinical outcomes were similar between men and women not achieving the early NT-proBNP goal (blue and red dashed lines). However,
separation of the solid curves suggests a trend towards fewer events among women achieving the early NT-proBNP goal compared
with men achieving the early NT-proBNP goal.

fewer clinical events compared with men. This would
be consistent with previous studies that have demonstrated better clinical outcomes among women with
HFrEF.3,13
Early achievement of the NT-
proBNP goal of
≤1000 pg/mL is associated with significantly better
outcomes than those not attaining goal.20 After adjustment for clinical risk and HF treatment through
3 months, there was no sex difference in the ability
to achieve the early NT-proBNP goal of ≤1000 pg/
mL. However, women achieving the NT-proBNP goal
of ≤1000 pg/mL at 3 months had a clinically significant lower rate of death and HF hospitalization than
men achieving the early NT-proBNP goal (82% versus 59%, respectively). This difference did not meet
statistical significance, likely because of the smaller
number of patients in the landmark analysis and fewer
events that consequently limited the power to detect
a statistical difference. Nonetheless, these findings
are still clinically meaningful and extend the current
knowledge by suggesting that the early NT-proBNP
goal of ≤1000 pg/mL may have greater prognostic
significance in women than men. This finding is further supported by the observation that the prespecified therapeutic NT-proBNP goal of ≤1000 pg/mL

was over 5 times lower than the adjusted NT-proBNP
threshold of 5410 pg/mL needed for risk reduction
in men; however, it was only minimally lower than
the adjusted NT-proBNP threshold of 1260 pg/mL
needed for women to demonstrate a reduction in adverse events. In other words, since the sex-specific
NT-proBNP threshold for risk reduction was lower
in women, there was greater benefit with incremental NT-proBNP reductions than in men, whose sex-
specific NT-proBNP threshold was higher. This likely
explains why women derived greater clinical benefit
from lower NT-proBNP concentrations at 3 months
than men.

Limitations
Several caveats should be considered in the interpretation of these results. First, women only comprised one third of the GUIDE-IT study population;
therefore, it is possible that additional sex differences exist but were not detected because of the
sample size and the abbreviated follow-u p period
with a relatively low number of events secondary to early trial termination. Efforts are needed to
achieve equity in trial enrollment so that when sex
differences exist, they can be detected and used
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to inform sex-
s pecific HF management. Second,
although this study included an in-d epth analysis
of treatment differences between men and women
with HFrEF, treatment with neprilysin inhibitors, a
therapy that can lead to substantial NT-p roBNP reduction, was not common in clinical practice during the timeframe in which the GUIDE IT trial was
conducted. However, neprilysin inhibition does not
appear to have a differential effect in men compared with women.29,30 Finally, a landmark analysis
at 12 months may have revealed whether the less
intense GDMT in women negatively impacted NT-
proBNP goal achievement and clinical outcomes
more than men. Yet, such an analysis would have
low power to detect a difference attributable to an
even smaller population than in the 3-m onth landmark subgroup, which may not reflect the overall
GUIDE-IT population as a result of survivor bias,
and been limited by shorter follow-
u p duration
with fewer events. Furthermore, the clinical value
of a 12-
m onth NT-
p roBNP analysis is uncertain.
In contrast, the 3-
m onth landmark is informative
for guiding clinical management and informing the
prognosis of men and women with HFrEF.

CONCLUSIONS
Downloaded from http://ahajournals.org by on June 13, 2021

This study revealed several important insights on HF
treatment, NT-
proBNP response, and clinical outcomes among men and women with HFrEF. Women
were undertreated with regards to target dosing of β-
blockers and ACEIs or ARBs. Future efforts should be
aimed at intensifying GDMT, achieving target doses,
and reducing NT-proBNP in women, which may have
even greater benefit for women than men.
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Table S1. Baseline Clinical Characteristics of Men and Women with NT-proBNP at 3
months.
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Women
(n=217)

Men
(n=480)

P-value

Age (years)

59.9±15.1

62.0±12.8

0.18

Race (Black)

97 (44.7%)

148 (30.8%)

<0.001

Body mass index (kg/m2)

32.5±10.1

29.4±7.1

<0.001

Hypertension

155 (71.4%)

391 (81.5%)

0.004

Hyperlipidemia

120 (55.3%)

288 (60.0%)

0.25

Diabetes mellitus

109 (50.2%)

213 (44.4%)

0.16

Smoking

52 (24.0%)

174 (36.3%)

0.001

Atrial fibrillation

72 (33.2%)

206 (42.9%)

0.02

Chronic kidney disease

63 (29.0%)

186 (38.8%)

0.01

Peripheral artery disease

8 (3.7%)

61 (12.7%)

<0.001

Coronary artery disease

68 (31.3%)

245 (51.0%)

<0.001

Myocardial infarction

38 (17.5%)

155 (32.3%)

<0.001

Ischemic cardiomyopathy

75 (34.6%)

267 (55.6%)

<0.001

Heart Failure Duration* (mos)

6 (1.0-45.0)

20 (1.0-72.0)

0.003

NYHA Class III/IV

88 (40.6%)

195 (41.1%)

0.93

25.0±8.3

23.9±8.4

0.09

106 (48.8%)

243 (50.6%)

0.68

54.5±21.0

59.9±22.1

0.002

Ejection Fraction (%)
Biomarker-guided Therapy
Quality of Life Score by KCCQ

Values are mean±SD or n (%). *Median (interquartile range) NYHA= New York Heart Association; KCCQ= Kansas City
Cardiomyopathy Questionnaire

Figure S1. Relationship between 3-month NT-proBNP and Death or HF Hospitalization.
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B. Men with HFrEF
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The vertical red line indicates the inflection point at which there was a significant decrease in the
adjusted hazard for death or HF hospitalization (women: 1260 pg/ml; men: 5410 pg/ml).

